Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/9309
Full metadata record
DC FieldValueLanguage
dc.contributor.authorCooper, Mark Een
dc.contributor.authorWebb, R Len
dc.contributor.authorde Gasparo, Men
dc.date.accessioned2015-05-15T22:21:36Z
dc.date.available2015-05-15T22:21:36Z
dc.date.issued2001en
dc.identifier.citationCardiovascular Drug Reviews; 19(1): 75-86en
dc.identifier.govdoc11314602en
dc.identifier.otherPUBMEDen
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/9309en
dc.description.abstractThis review deals with similarities and differences between the effects of ACE inhibitors and AT1-receptor blockers in the kidney. Specific receptor blockade has demonstrated that the beneficial effects of AT1 blockers arise from two mechanisms: the reduction of the AT1 receptor mediated response and the increase in plasma levels of Ang II through the AT1-receptor blockade, which leads to increased stimulation of the AT2 receptor (the so-called yin-yang effect). Both ACE inhibition and AT1-receptor blockade provide significant renal protection in the majority of experimental animal models of kidney diseases. AT1 receptor blockade may offer additional clinical benefits over ACE inhibitor treatment, particularly in the kidney, where AT1-receptor blockade does not cause the fall in glomerular filtration rate seen with ACE inhibitor treatment. A number of long-term clinical studies currently running should show the real value of this new class of compounds in the management of hypertension and associated cardiorenal diseases.en
dc.language.isoenen
dc.subject.otherAngiotensin II.blooden
dc.subject.otherAngiotensin Receptor Antagonistsen
dc.subject.otherAngiotensin-Converting Enzyme Inhibitors.pharmacology.therapeutic useen
dc.subject.otherAnimalsen
dc.subject.otherDiabetes Mellitus.drug therapy.physiopathologyen
dc.subject.otherDisease Models, Animalen
dc.subject.otherHumansen
dc.subject.otherHypertension.drug therapyen
dc.subject.otherKidney.drug effects.metabolismen
dc.subject.otherKidney Diseases.prevention & controlen
dc.subject.otherKidney Failure, Chronic.drug therapyen
dc.subject.otherRatsen
dc.subject.otherReceptor, Angiotensin, Type 1en
dc.subject.otherReceptor, Angiotensin, Type 2en
dc.titleAngiotensin receptor blockers and the kidney: possible advantages over ACE inhibition?en
dc.typeJournal Articleen
dc.identifier.journaltitleCardiovascular drug reviewsen
dc.identifier.affiliationUniversity of Melbourne, Department of Medicine, Austin and Repatriation Medical Center, West Heidelberg, Victoria, Australiaen
dc.description.pages75-86en
dc.relation.urlhttps://pubmed.ncbi.nlm.nih.gov/11314602en
dc.type.austinJournal Articleen
item.openairetypeJournal Article-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.grantfulltextnone-
item.fulltextNo Fulltext-
item.cerifentitytypePublications-
item.languageiso639-1en-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

8
checked on Mar 27, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.